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Introduction
Craniofacial hyperhidrosis (CFH), a condition of excessive 
sweating of the head and face, is one of the most common 
cardinal symptoms of social phobia (1). Those with 
this condition may also likely experience a significant 
deterioration in the quality of life (2). Hence, to overcome 
these problems of CFH and to return to normal daily 
activities with self-esteem, treatment of CFH is highly 
recommended. 
It has previously been established that CFH accounts 
for only 22.8% of all primary hyperhidrosis and is different 
from other forms of focal hyperhidrosis that are more 
common amongst males and elderly patients (3). Hence, 
primary CFH should be considered only after ruling out 
secondary conditions, such as menopause, diabetes mellitus, 
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endocrine disorders, and certain medications, including 
hydrochloride and pilocarpine (4). 
Endoscopic thoracic sympathectomy (ETS) has been 
considered as a definite treatment method for primary 
hyperhidrosis (5-9). It has been widely utilized for palmar 
and axillary hyperhidrosis, due not only to the relative ease 
of accessibility and short recovery time necessary, but also to 
its high success rate. Despite its wide application, however, 
to the best our knowledge, there have been only a few 
studies evaluating the applicability of ETS for CFH and risk 
of postoperative compensatory hyperhidrosis. Moreover, 
many institutions are avoiding surgical approaches to treat 
CFH due to compensatory hyperhidrosis after ETS. This 
motivated our team to develop a new method of ETS 
to minimize the degree and locations of postoperative 
compensatory hyperhidrosis, with the ultimate goal of 
reducing social phobia and discomfort in daily life in 
our patients. Therefore, this study attempted to examine 
whether our newly developed method of ETS is safe and 
efficient for managing CFH, and to analyze postoperative 
compensatory hyperhidrosis based on early results. 
Methods
Patients and clinical data
We retrospectively analyzed the medical records of 72 
patients who underwent ETS with our new technique for 
primary CFH between June 2016 and October 2017. All 
operations were performed on an outpatient basis. We 
excluded patients with severe pleural adhesion (n=1) and 
those who underwent previous thoracic surgery (n=1). The 
data were collected by a manual review of the electronic 
records of patients, which consisted of information on 
preoperative characteristics, disease status, operative 
technique, and postoperative outcomes. Moreover, we 
interviewed patients using a telephone questionnaire 
that has previously been reported, with modification, in 
June 2015 (10). The questionnaire included the degree of 
craniofacial sweating, grade of compensatory hyperhidrosis, 
and recurrence/failure. The degree of craniofacial sweating 
was defined as a percentage of post-operative craniofacial 
sweating compared with pre-operative craniofacial sweating. 
The grade of compensatory hyperhidrosis was categorized as 
none, mild (not bothering), moderate (sometimes bothering), 
severe (often bothering), or very severe (intolerable). The 
grade of satisfaction was categorized as very satisfied, satisfied, 
moderate, dissatisfied, or very dissatisfied. Recurrence or 
failure was considered in patients presented with a residual 
craniofacial sweating of 40% for those who underwent 
new ETS. This retrospective study was approved by the 
local institutional review board at the Gangnam Severance 
Hospital Korea, and the requirement for informed consent 
was waived due to its retrospective nature.
Surgery
All patients, while under general anesthesia via one-lung 
ventilation in lateral decubitus position, underwent ETS 
with our new technique, using a bilateral simultaneous two-
portal video-assisted thoracoscopic surgery (VATS). The new 
technique for ETS involved R2 and R4–R7 sympathectomy 
with R4–R7 truncal ablation using a CO2 gas instillation. 
Two tiny incisions of 2 and 3 mm were made on each side; 
the incision for 2 mm-thoracoscope was made at the 6th 
intercostal space (ICS) on the mid-axillary line, and the 
incision for instruments was made at the 5th ICS on the 
anterior axillary line. When performing R2 sympathectomy, 
the costal pleura on the surface of the sympathetic chain 
were transected at the level of the second lower rib bed with 
diathermy. To complete the transection of the potential 
bypass nerve fibers, we extended the transection range by 
approximately 2 cm, laterally along the surface; we then 
performed R4, R5, R6, and R7 sympathectomy and R4–
R7 truncal ablation to prevent upper body hyperhidrosis 
(Figure 1). We routinely conducted the operation on the 
right side first, to get a view of the imbalanced innervation 
of the heart by bilateral sympathetic nerves (7). The 
corresponding procedure was performed on the left side. A 
10-Fr chest tube was placed in the pleural cavity, the lung 
was inflated, and the chest tube was removed once the air 
ceased to escape. Postoperative routine chest radiography 
was obtained in all patients prior to extubation in the 
operating room for the early detection of pneumothorax. 
Most patients were discharged on the same day or the 
following day. 
Statistical analysis
All descriptive statistics are presented as the mean ± 
standard deviation (SD) for continuous variables. All 
statistical analyses were performed using SPSS statistical 
software version 21.0 (SPSS, Inc., Chicago, IL, USA).
Results
A total of 70 patients who underwent ETS using our new 
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technique were included in this study. All procedures were 
performed bilaterally. Among these patients, 55 patients 
were male (78.6%), and the mean age was 48 years, with a 
range of 22–75 years. The median operation time was 38 
minutes, with a range of 28–75 minutes (Table 1). 
Bilateral ETS using our new technique was successful 
in all patients. There were no operative mortalities or 
major morbidities. The immediate operative results were 
excellent; all patients showed significant improvement 
with respect to sweating of the head and face. The median 
follow-up duration was 7 months (range, 1–17 months); 
68 patients (97.1%) developed compensatory sweating in 
the lower limbs and lower trunk (Figure 2). The degree of 
compensatory hyperhidrosis was mostly mild to moderate 
in most patient (92.9%, 65/70); only 5 patients reported 
having severe compensatory hyperhidrosis in the lower 
abdomen and thigh with slight disturbance to everyday life. 
In terms of satisfaction, 46 (65.7%) patients were “very 
satisfied” and 24 (34.4%) patients were “satisfied” (Table 2). 
Neither transient nor permanent Horner’s syndrome 
occurred in any patient. We did not observe any patient 
with recurrence or failure of ETS using our new technique.
Discussion
Hyperhidrosis is defined as a pathologic condition 
characterized by excessive sweating (5). Although it is 
mainly a physical burden, hyperhidrosis can also negatively 
impact the psychological, emotional, and social well-
being of an individual, severely debilitating one’s quality 
of life (5,11). More specially, CFH, which is a condition 
Figure 1 New endoscopic thoracic sympathectomy technique for 
craniofacial hyperhidrosis: R2 and R4–R7 sympathectomy with 
R4–R7 truncal ablation. 
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Table 1 Patients’ characteristics in the new endoscopic thoracic  
sympathectomy for craniofacial  hyperhidrosis  and early  
postoperative outcomes
Variables
New ETS patients 
(n=70)
Age (years), mean ± SD [range] 48±13 [22–75]
Male/female 55/15
BMI (kg/m2), mean ± SD 26.40±3.40
Main trigger for hyperhidrosis, n (%)
Heat 36 (51.4)
Gustatory 24 (34.3)
Emotion 3 (4.3)
Exercise 7 (10.0)
Operation time (minutes), median [range] 38 [28–75]
Immediate symptom relief, n (%) 70 (10.0)
Operative complication, n (%) 17 (24.3)
Follow-up duration (months), median [range] 7 [1–17]
Compensatory sweating, n (%)
None-mild 52 (74.3)
Moderate-severe-very severe 18 (25.7)
Satisfaction, n (%)
Very satisfied-satisfied-moderate 70 (100.0)
Dissatisfied-very dissatisfied 0 (0.0)
Recurrence/failure, n (%) 0 (0.0)
SD, standard deviation; BMI, body mass index; ETS, endoscopic  
thoracic sympathectomy.
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Table 2 Grades of compensatory hyperhidrosis and satisfaction 
after new endoscopic thoracic sympathectomy for craniofacial  
hyperhidrosis
Variables New ETS patients (n=70)
Compensatory sweating, n (%)
Mild 2 (2.9)
Moderate 50 (71.4)
Severe 13 (18.6)
Very severe 5 (7.1)
Satisfaction, n (%)
Very satisfied 46 (65.7)
Satisfied 24 (34.3)
Moderate –
Dissatisfied –
Very dissatisfied –
ETS, endoscopic thoracic sympathectomy.
Figure 2 Frequency of compensatory hyperhidrosis sites. 
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of excessive local sweating, on the head and face, is often 
associated with mental stress (1). Patients suffering from 
CFH are considered to be seriously handicapped, both 
socially and psychologically (2). Nonetheless, CFH has 
been a clinical problem overshadowed by palmar, plantar, 
and axillary hyperhidrosis. 
Since Drott et al. recommended ablation of the first 
ganglion to manage CFH patients, several studies have 
presented satisfying results, and since then, the operative 
method has evolved (6). Still, the surgical approach of 
transecting the sympathetic chain in the lower margin 
of the second rib or in the lower third of the stellate 
ganglion level has been standardized and utilized in 
most institutions (9). An accurate identification of the 
second rib is very important. The superior intercostal 
artery, which arises from the subclavian artery, is very 
important in identifying the second rib. Lin and their 
colleagues suggested that the first intercostal muscle may 
be the best method in identifying of the second rib (2). 
After undergoing surgery to treat CFH, the incidence 
of Horner’s syndrome has been reported to be between 
0% and 3.3% (2,5,9). In our study, we did not have any 
incidence of Horner’s syndrome. Thus, a transection of the 
lower third of the stellate ganglion or the lower margin of 
R2 does not result in Horner’s syndrome. 
ETS is an elective procedure with great potential 
benefits. However, it is also associated with some significant 
risks. The major complication of the ETS is the high 
rates of compensatory hyperhidrosis (8). Postoperative 
compensatory hyperhidrosis after a standard ETS, which 
is usually performed at T2, is common in the buttocks, 
chest, upper limbs and lower limbs; but it is not limited to 
these areas and can manifest in other parts of the body (1). 
Although a clear mechanism for these complications has 
not been fully elucidated thus far, it has been proposed that 
a thermoregulatory response may be associated (2). Those 
who develop postoperative compensatory hyperhidrosis 
tend to regret receiving ETS for CFH, as they are left with 
a similar condition, just at another location of their body, 
posing a similar debilitative condition (12). Lin TS and 
their colleagues reported that 85.7% who underwent ETS 
for CFH developed compensatory hyperhidrosis, and 48% 
of them developed compensatory hyperhidrosis in lower 
chest and abdomen areas (2). 
Given such high incidence of postoperative compensatory 
hyperhidrosis using the standard ETS for CFH, we used the 
following logic in developing our approach: If postoperative 
compensatory hyperhidrosis is unavoidable in most cases, 
we may be able to obtain greater satisfaction if we could 
localize the site of compensatory hyperhidrosis to the 
lower extremity. To achieve this, R4–R7 sympathectomy 
with truncal ablation, in addition to the conventional R2 
sympathectomy was performed. R4–R7 sympathectomy was 
performed to eliminate compensatory hyperhidrosis in the 
upper part trunk, and R4–R7 truncal ablation was performed 
to provide similar advantages of sympathectomy. As expected, 
we observed a high incidence (97.1%) of compensatory 
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hyperhidrosis in our study population. However, we were 
able to achieve localization of compensatory hyperhidrosis 
to the lower extremity, with no incidence of postoperative 
compensatory sweating in the chest area. We observed five 
patients with severe compensatory hyperhidrosis in the waist 
and lower abdomen. These patients are currently receiving 
oxybutynin at the outpatient clinic and are reporting that 
their compensatory hyperhidrosis is under control without 
much interference with daily living. It is unclear why, despite 
the same procedural approach, there is a variance in the 
degree and location of compensatory hyperhidrosis between 
individuals. To better understand and such variance, a future 
study analyzing the risk factors is warranted. Nonetheless, all 
our patients were satisfied with the operation, and reported 
that postoperative compensatory hyperhidrosis was relatively 
tolerable. 
There are some limitations to consider when interpreting 
our findings. Our study included a small number of 
sample size, with a short follow-up duration. In addition, 
compensatory hyperhidrosis and symptoms of our patients 
were not measured in an objective manner; they were based 
on a survey. A future study with larger sample size and longer 
follow-up duration with objective indicators are necessary.
Conclusions
We believe that this study is meaningful in that it 
provides a new surgical approach to overcome the issue of 
compensatory hyperhidrosis. Although ETS may not be the 
treatment of choice for CFH, our method of ETS offers a 
relatively safe and efficient treatment option for those who 
do not respond to other conservative treatments, such as 
topical glycopyrrolate, oral oxybutynin, and intradermal 
botulinum toxin A injection.
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